FDA 483 - BioMarin Pharmaceutical Inc. - February 18, 2014
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of BioMarin Pharmaceutical, Inc. in San Rafael, CA, a drug manufacturer, revealed a significant deficiency in their pharmacovigilance system. The firm failed to develop written procedures for the surveillance of post-marketing adverse drug experiences. This oversight resulted in specialty pharmacies, which dispense their products like Kuvan and Naglazyme, not being audited for pharmacovigilance compliance, potentially leading to unreported adverse drug experiences.
ID · e6630c14-6a99-465e-bfaa-7ffad255012d